# Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

> **NCT03904069** · PHASE1 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** AMG 553

## Key facts

- **NCT ID:** NCT03904069
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-13
- **Primary completion:** 2030-08-07
- **Final completion:** 2030-08-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03904069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03904069, "Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03904069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*